Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1994 1
1995 1
1996 3
1997 2
1998 1
1999 2
2000 1
2001 3
2002 4
2003 3
2004 2
2005 4
2006 1
2007 1
2008 5
2009 10
2010 3
2011 4
2012 5
2013 4
2014 8
2015 4
2016 8
2017 5
2018 4
2019 4
2020 6
2021 13
2022 7
2023 8
2024 7
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach AE, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. Herrera AF, et al. Among authors: tuscano jm. N Engl J Med. 2024 Oct 17;391(15):1379-1389. doi: 10.1056/NEJMoa2405888. N Engl J Med. 2024. PMID: 39413375 Free PMC article. Clinical Trial.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. Zelenetz AD, et al. Among authors: tuscano j. J Natl Compr Canc Netw. 2023 Nov;21(11):1118-1131. doi: 10.6004/jnccn.2023.0057. J Natl Compr Canc Netw. 2023. PMID: 37935098
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.
Rutherford SC, Li H, Herrera AF, LeBlanc M, Ahmed S, Davison K, Parsons SK, Unger JM, Perry AM, Casulo C, Bartlett NL, Tuscano JM, Hess BT, Torka P, Kumar P, Jacobs R, Song JY, Castellino SM, Kahl B, Leonard JP, Smith SM, Friedberg JW, Evens AM. Rutherford SC, et al. Among authors: tuscano jm. J Clin Oncol. 2025 Sep 20;43(27):2968-2973. doi: 10.1200/JCO-25-00204. Epub 2025 Jun 16. J Clin Oncol. 2025. PMID: 40523203 Clinical Trial.
Checkpoint inhibition in hematologic malignancies.
Tsumura A, Levis D, Tuscano JM. Tsumura A, et al. Among authors: tuscano jm. Front Oncol. 2023 Oct 17;13:1288172. doi: 10.3389/fonc.2023.1288172. eCollection 2023. Front Oncol. 2023. PMID: 37920162 Free PMC article. Review.
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.
Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. Chavez JC, et al. Among authors: tuscano jm. Clin Cancer Res. 2023 May 15;29(10):1869-1878. doi: 10.1158/1078-0432.CCR-22-2955. Clin Cancer Res. 2023. PMID: 36826995 Free PMC article.
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.
Othman T, Frankel P, Allen P, Popplewell LL, Shouse G, Siddiqi T, Danilov AV, Ruel N, Daniels S, Peters L, Khoo S, Rosen ST, Sharon E, Villalona-Calero M, Ruel C, Tuscano J, Herrera AF. Othman T, et al. Among authors: tuscano j. Haematologica. 2025 Jan 1;110(1):142-152. doi: 10.3324/haematol.2024.285185. Haematologica. 2025. PMID: 39021209 Free PMC article. Clinical Trial.
126 results